The combination of navitoclax and ruxolitinib simultaneously inhibits 2 important mechanisms that boost myelofibrosis, resulting in an advancement in symptom Command and optimistic modifications in response biomarkers in individuals with significant-risk condition.It blocks a gene  known as JAK2. By blocking JAK2 ruxolitinib slows down or stops th